Clinical oncology NGS market seen reaching $1.04 billion by 2030

The clinical oncology next generation sequencing market is projected to climb from $0.58 billion in 2025 to $1.04 billion by 2030, driven by rising cancer cases, precision oncology demand and wider use of molecular diagnostics. North America held the largest share in 2025, while Asia-Pacific ranked second with room to expand.

Why it matters: - Clinical oncology next generation sequencing is becoming a core tool for precision cancer care. - The market’s growth reflects rising demand for tests that can identify rare mutations and help match patients with targeted therapies. - The report ties market expansion to the broader increase in global cancer incidence.

What happened: - The Business Research Company released its Clinical Oncology Next Generation Sequencing Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The market is projected to grow from $0.58 billion in 2025 to $0.66 billion in 2026. - The report forecasts the market will reach $1.04 billion by 2030. - The 2025-2026 period implies a 13.3% compound annual growth rate. - The 2026-2030 forecast implies a 12.1% compound annual growth rate.

The details: - Next generation sequencing, or NGS, maps the order of nucleotides in DNA segments. - In oncology, NGS helps identify rare cancer-related mutations and familial cancer mutation carriers. - The technology supports selection of targeted therapies based on individual tumor profiles. - Historical growth was driven by cancer genomics research, wider sequencing platform access, more oncology clinical trials, greater use of molecular diagnostics and lower sequencing costs. - Forecast growth is linked to rising demand for precision oncology treatments, more investment in genomic medicine, new hospital-based sequencing labs, broader use of targeted cancer therapies and continued improvements in sequencing methods. - The report highlights growth in NGS-based oncology diagnostics, companion diagnostic applications, bioinformatics integration, personalized treatment strategies and rare-mutation detection. - In February 2024, the World Health Organization projected more than 35 million new cancer cases by 2050, a 77% increase from about 20 million cases in 2022. - North America held the largest market share in 2025. - Asia-Pacific ranked second and shows strong growth potential. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests clinical oncology NGS is moving from a specialized research tool toward broader routine use in care delivery. - Hospital-based sequencing labs and better bioinformatics point to a market that is shifting from raw sequencing capacity toward end-to-end clinical decision support. - The rising cancer burden gives the market a long-term demand tail, even as growth rates moderate slightly in the later forecast period.

What's next: - The report expects continued expansion as precision oncology adoption widens and sequencing workflows become more embedded in clinical settings. - Future demand will likely track advances in targeted therapies, companion diagnostics and mutation detection. - The company offers a free sample of the report and the full market report.

The bottom line: - Clinical oncology next generation sequencing is set for sustained growth as cancer prevalence rises and precision medicine becomes more central to treatment.